JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on June 20, 2007; DOI: 10.1124/jpet.107.121699


This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
jpet.107.121699v1
322/3/1171    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oakes, C. C
Right arrow Articles by Trasler, J. M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oakes, C. C
Right arrow Articles by Trasler, J. M


Received for publication February 21, 2007.
Revised June 19, 2007.
Accepted for publication June 20, 2007.

Adverse effects of 5-aza-2’-deoxycytidine on spermatogenesis include reduced sperm function and selective inhibition of de novo DNA methylation

Christopher C Oakes 1, Tamara LJ Kelly 1, Bernard Robaire 1, Jacquetta M Trasler 1*

1 McGill University

* Address correspondence to: E-mail: jacquetta.trasler{at}mcgill.ca

Abstract

The anti-cancer agent, 5-aza-2'-deoxycytidine (5-azaCdR, Decitabine), causes DNA hypomethylation and a robust, dose-dependent disruption of spermatogenesis. Previously we have shown that altered testicular histology and reduced sperm production in 5-azaCdR-treated animals is associated with decreased global sperm DNA methylation and an increase in infertility and/or a decreased ability to support preimplantation embryonic development. The goal of this study was to determine potential contributors to 5-azaCdR-mediated infertility including alterations in sperm motility, fertilization ability, early embryo development and sequence-specific DNA methylation. We find that although 5-azaCdR-treatment adversely affected sperm motility and the survival of sired embryos to the blastocyst stage, the major contributor to infertility was a marked (56-70%) decrease in fertilization ability. Sperm DNA methylation was investigated using Southern blot, restriction landmark genomic scanning, and quantitative analysis of DNA methylation by real-time PCR. Interestingly, hypomethylation was restricted to genomic loci that have been previously determined to acquire methylation during spermatogenesis, demonstrating that 5-azaCdR selectively inhibits de novo methylation activity. Similar to previous studies, we show that mice that are heterozygous for a non-functional Dnmt1 gene are partially protected against the deleterious effects of 5-azaCdR; however, methylation levels are not restored in these mice, suggesting that adverse effects are due to another mechanism(s) in addition to DNA hypomethylation. These results demonstrate that clinically relevant doses of 5-azaCdR specifically impair de novo methylation activity in male germ cells; however, genotype-specific differences in drug responses suggest that adverse reproductive outcomes are mainly mediated by the cytotoxic properties of the drug.


Key words: 5-aza-2’-deoxycytidine, DNA methylation, Decitabine, Germ Cell, RLGS, Spermatogenesis


This article has been cited by other articles:


Home page
Biol. Reprod.Home page
M. G. Wade, A. Kawata, A. Williams, and C. Yauk
Methoxyacetic Acid-Induced Spermatocyte Death Is Associated with Histone Hyperacetylation in Rats
Biol Reprod, May 1, 2008; 78(5): 822 - 831.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.